1-20 of 36
Peter J. Houghton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma

Brian Mooney, Gian Luca Negri, Taras Shyp, Alberto Delaidelli, Hai-Feng Zhang, Sandra E. Spencer Miko, Amber K. Weiner, Alexander B. Radaoui, Rawan Shraim, Michael M. Lizardo, Christopher S. Hughes, Amy Li, Amal M. El-Naggar, Melanie Rouleau, Wei Li, Dimiter S. Dimitrov, Raushan T. Kurmasheva, Peter J. Houghton, Sharon J. Diskin, John M. Maris, Gregg B. Morin, Poul H. Sorensen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (5): 1022–1037.
https://doi.org/10.1158/1078-0432.CCR-23-2187
Published: 01 March 2024
View article titled, Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Open the PDF for Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma in another window
Includes: Supplementary data
Journal Articles

Abstract A009: Proteogenomic prioritization of immunotherapeutic targets in rhabdomyosarcoma nominate MEGF10 for preclinical development

Rawan Shraim, Amber K. Weiner, Karina L. Conkrite, Alexander B. Radaoui, John M. Maris, Yael P. Mosse, Sharon J. Diskin, Ahmet Sacan, Benjamin A. Garcia, Peter J. Houghton, Raushan T. Kurmasheva, Poul Sorensen, Gregg B. Morin, Brian Mooney
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): A009.
https://doi.org/10.1158/1557-3265.SARCOMAS22-A009
Published: 15 September 2022
View article titled, Abstract A009: Proteogenomic prioritization of immunotherapeutic targets in rhabdomyosarcoma nominate MEGF10 for preclinical development
Journal Articles

Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models

Fuyang Li, Kathryn M. Bondra, Samson Ghilu, Adam Studebaker, Qianqian Liu, Joel E. Michalek, Mari Kogiso, Xiao-Nan Li, John A. Kalapurakal, C. David James, Sandeep Burma, Raushan T. Kurmasheva, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3836–3849.
https://doi.org/10.1158/1078-0432.CCR-22-1052
Published: 01 September 2022
View article titled, Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <em>BRAF<sup>V600E</sup></em> Brain Tumor Models
Open the PDF for Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <em>BRAF<sup>V600E</sup></em> Brain Tumor Models in another window
Includes: Supplementary data
Journal Articles

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Nathan M. Kendsersky, Jarrett Lindsay, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, Eric J. Earley, Yael P. Mosse, Daniel Martinez, Jennifer Pogoriler, Kateryna Krytska, Khushbu Patel, David Groff, Matthew Tsang, Samson Ghilu, Yifei Wang, Steven Seaman, Yang Feng, Brad St. Croix, Richard Gorlick, Raushan Kurmasheva, Peter J. Houghton, John M. Maris
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2938–2946.
https://doi.org/10.1158/1078-0432.CCR-20-4221
Published: 15 May 2021
View article titled, The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
Open the PDF for The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models in another window
Includes: Supplementary data
Journal Articles

Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts

Andrew J. Robles, Raushan T. Kurmasheva, Abhik Bandyopadhyay, Doris A. Phelps, Stephen W. Erickson, Zhao Lai, Dias Kurmashev, Yidong Chen, Malcom A. Smith, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 3012–3023.
https://doi.org/10.1158/1078-0432.CCR-19-1822
Published: 15 June 2020
View article titled, Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts
Open the PDF for Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

Yael P. Mossé, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Safgren, Hernan Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barkauskas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, Brenda J. Weigel
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3229–3238.
https://doi.org/10.1158/1078-0432.CCR-18-2675
Published: 03 June 2019
View article titled, A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Open the PDF for A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) in another window
Includes: Supplementary data
Journal Articles

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Caitlin D. Lowery, Michele Dowless, Matthew Renschler, Wayne Blosser, Alle B. VanWye, Jennifer R. Stephens, Philip W. Iversen, Aimee Bence Lin, Richard P. Beckmann, Kateryna Krytska, Kristina A. Cole, John M. Maris, Douglas S. Hawkins, Brian P. Rubin, Raushan T. Kurmasheva, Peter J. Houghton, Richard Gorlick, E. Anders Kolb, Min H. Kang, C. Patrick Reynolds, Stephen W. Erickson, Beverly A. Teicher, Malcolm A. Smith, Louis F. Stancato
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2278–2289.
https://doi.org/10.1158/1078-0432.CCR-18-2728
Published: 01 April 2019
View article titled, Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
Open the PDF for Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models in another window
Includes: Supplementary data
Journal Articles

Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL

Luke Jones, Jennifer Richmond, Kathryn Evans, Hernan Carol, Duohui Jing, Raushan T. Kurmasheva, Catherine A. Billups, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3744–3755.
https://doi.org/10.1158/1078-0432.CCR-16-2392
Published: 13 July 2017
View article titled, Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL
Open the PDF for Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL in another window
Includes: Supplementary data
Journal Articles

Abstract IA15: Promise and challenges of pediatric cancer PDX models

Peter J. Houghton, Raushan T. Kurmasheva
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): IA15.
https://doi.org/10.1158/1557-3265.PDX16-IA15
Published: 15 August 2016
View article titled, Abstract IA15: Promise and challenges of pediatric cancer PDX models
Journal Articles

A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Maryam Fouladi, John P. Perentesis, Lars M. Wagner, Alexander A. Vinks, Joel M. Reid, Charlotte Ahern, George Thomas, Carol A. Mercer, Darcy A. Krueger, Peter J. Houghton, L. Austin Doyle, Helen Chen, Brenda Weigel, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1558–1565.
https://doi.org/10.1158/1078-0432.CCR-14-0595
Published: 31 March 2015
View article titled, A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Open the PDF for A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report in another window
Includes: Supplementary data
Journal Articles

Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

Jennifer Richmond, Hernan Carol, Kathryn Evans, Laura High, Agnes Mendomo, Alissa Robbins, Claus Meyer, Nicola C. Venn, Rolf Marschalek, Michelle Henderson, Rosemary Sutton, Raushan T. Kurmasheva, Ursula R. Kees, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1395–1405.
https://doi.org/10.1158/1078-0432.CCR-14-2300
Published: 12 March 2015
View article titled, Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <em>MLL</em>-Rearranged Acute Lymphoblastic Leukemia
Open the PDF for Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant <em>MLL</em>-Rearranged Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Gorlick, Hernan Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 819–832.
https://doi.org/10.1158/1078-0432.CCR-14-2572
Published: 16 February 2015
View article titled, Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Open the PDF for Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program in another window
Includes: Supplementary data
Journal Articles

Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts

Santi Suryani, Hernan Carol, Triona Ni Chonghaile, Viktoras Frismantas, Chintanu Sarmah, Laura High, Beat Bornhauser, Mark J. Cowley, Barbara Szymanska, Kathryn Evans, Ingrid Boehm, Elise Tonna, Luke Jones, Donya Moradi Manesh, Raushan T. Kurmasheva, Catherine Billups, Warren Kaplan, Anthony Letai, Jean-Pierre Bourquin, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4520–4531.
https://doi.org/10.1158/1078-0432.CCR-14-0259
Published: 01 September 2014
View article titled, Cell and Molecular Determinants of <em>In Vivo</em> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Open the PDF for Cell and Molecular Determinants of <em>In Vivo</em> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts in another window
Includes: Supplementary data
Journal Articles

Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

Chand Khanna, Timothy M. Fan, Richard Gorlick, Lee J. Helman, Eugenie S. Kleinerman, Peter C. Adamson, Peter J. Houghton, William D. Tap, Danny R. Welch, Patricia S. Steeg, Glenn Merlino, Poul H.B. Sorensen, Paul Meltzer, David G. Kirsch, Katherine A. Janeway, Brenda Weigel, Lor Randall, Stephen J Withrow, Melissa Paoloni, Rosandra Kaplan, Beverly A. Teicher, Nita L. Seibel, Malcolm Smith, Aykut Üren, Shreyaskumar R. Patel, Jeffrey Trent, Sharon A. Savage, Lisa Mirabello, Denise Reinke, Donald A. Barkaukas, Mark Krailo, Mark Bernstein
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4200–4209.
https://doi.org/10.1158/1078-0432.CCR-13-2574
Published: 13 August 2014
View article titled, Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Open the PDF for Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma in another window
Journal Articles

FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene

Mamata Singh, Justin M. Leasure, Christopher Chronowski, Brian Geier, Kathryn Bondra, Wenrui Duan, Lauren A. Hensley, Miguel Villalona-Calero, Ning Li, Anthony M. Vergis, Raushan T. Kurmasheva, Changxian Shen, Gary Woods, Nikhil Sebastian, Denise Fabian, Rita Kaplon, Sue Hammond, Kamalakannan Palanichamy, Arnab Chakravarti, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (14): 3884–3895.
https://doi.org/10.1158/1078-0432.CCR-13-0556
Published: 14 July 2014
View article titled, FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
Open the PDF for FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene in another window
Includes: Supplementary data
Journal Articles

Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma

Hemant K. Bid, Aaron Kibler, Doris A. Phelps, Sagymbek Manap, Linlin Xiao, Jiayuh Lin, David Capper, Duane Oswald, Brian Geier, Mariko DeWire, Paul D. Smith, Raushan T. Kurmasheva, Xiaokui Mo, Soledad Fernandez, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6716–6729.
https://doi.org/10.1158/1078-0432.CCR-13-0842
Published: 16 December 2013
View article titled, Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an <em>In Vivo</em> Model of Childhood Astrocytoma
Open the PDF for Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an <em>In Vivo</em> Model of Childhood Astrocytoma in another window
Includes: Supplementary data
Journal Articles

Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy

Hemant K. Bid, Cheryl A. London, Jin Gao, Haihong Zhong, Robert E. Hollingsworth, Soledad Fernandez, Xiaokui Mo, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 2984–2994.
https://doi.org/10.1158/1078-0432.CCR-12-2008
Published: 30 May 2013
View article titled, Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy
Open the PDF for Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy in another window
Includes: Supplementary data
Journal Articles

The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia

Hernan Carol, Barbara Szymanska, Kathryn Evans, Ingrid Boehm, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1795–1805.
https://doi.org/10.1158/1078-0432.CCR-12-3613
Published: 02 April 2013
View article titled, The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Open the PDF for The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507

Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Addy C.M. van de Luijtgaarden, Janneke D.M. Molkenboer-Kuenen, Sandra Heskamp, Melissa H.S. Roeffen, Hanneke W.M. van Laarhoven, Peter J. Houghton, Wim J.G. Oyen, Otto C. Boerman, Winette T.A. van der Graaf
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7693–7703.
https://doi.org/10.1158/1078-0432.CCR-11-1488
Published: 18 December 2011
View article titled, Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507
Open the PDF for Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507 in another window
Includes: Supplementary data
Journal Articles

Everolimus

Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1368–1372.
https://doi.org/10.1158/1078-0432.CCR-09-1314
Published: 28 February 2010
View article titled, Everolimus
Open the PDF for Everolimus in another window